Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALLRNASDAQ:CMMBNASDAQ:MTEXNASDAQ:NCNA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALLRAllarity Therapeutics$1.13+5.6%$0.91$0.61▼$103.80$19.23M-0.061.06 million shs1.71 million shsCMMBChemomab Therapeutics$1.31+1.6%$1.30$0.60▼$2.55$18.81M0.66213,937 shs63,234 shsMTEXMannatech$11.25+4.7%$10.04$6.75▼$16.49$21.39M0.984,389 shs4,862 shsNCNANuCana$0.55-15.4%$0.86$0.55▼$10.79$3.13M1.46433,855 shs336,838 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALLRAllarity Therapeutics+5.94%+13.83%-3.60%-21.32%-97.40%CMMBChemomab Therapeutics+7.50%+15.18%+13.16%-37.98%+92.54%MTEXMannatech+10.82%+9.19%+11.92%-12.21%+31.74%NCNANuCana-25.29%-24.42%-18.75%-42.48%-83.03%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALLRAllarity Therapeutics0.1126 of 5 stars0.02.00.00.00.60.00.6CMMBChemomab Therapeutics2.8568 of 5 stars3.55.00.00.00.61.71.3MTEXMannatech0.8167 of 5 stars0.05.00.80.00.61.70.0NCNANuCana2.156 of 5 stars3.33.00.00.00.02.51.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALLRAllarity Therapeutics 0.00N/AN/AN/ACMMBChemomab Therapeutics 3.00Buy$9.00587.02% UpsideMTEXMannatech 0.00N/AN/AN/ANCNANuCana 2.50Moderate Buy$25.004,444.63% UpsideCurrent Analyst Ratings BreakdownLatest NCNA, MTEX, ALLR, and CMMB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails2/20/2025CMMBChemomab TherapeuticsMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$4.00 ➝ $7.00(Data available from 4/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALLRAllarity TherapeuticsN/AN/AN/AN/A($559.39) per shareN/ACMMBChemomab TherapeuticsN/AN/AN/AN/A$1.54 per shareN/AMTEXMannatech$117.87M0.18N/AN/A$5.64 per share1.99NCNANuCanaN/AN/AN/AN/A$8.85 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALLRAllarity Therapeutics-$11.90MN/A0.00N/AN/AN/A-369.67%-100.06%5/13/2025 (Estimated)CMMBChemomab Therapeutics-$24.22M-$0.90N/AN/AN/AN/A-101.70%-76.18%5/8/2025 (Estimated)MTEXMannatech-$2.24M$1.33N/A∞N/A-1.26%-15.62%-3.76%5/13/2025 (Estimated)NCNANuCana-$34.37M-$6.55N/AN/AN/AN/A-314.47%-112.60%5/15/2025 (Estimated)Latest NCNA, MTEX, ALLR, and CMMB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025N/ANCNANuCana-$0.01N/AN/AN/AN/AN/A5/13/2025N/AALLRAllarity Therapeutics-$8.10N/AN/AN/AN/AN/A5/8/2025Q1 2025CMMBChemomab Therapeutics-$0.20N/AN/AN/AN/AN/A3/26/2025Q4 2024MTEXMannatechN/A$1.20N/A$1.20N/A$29.01 million3/20/2025Q4 2024NCNANuCana-$2.43-$0.32+$2.11-$0.32N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALLRAllarity TherapeuticsN/AN/AN/AN/AN/ACMMBChemomab TherapeuticsN/AN/AN/AN/AN/AMTEXMannatech$0.201.78%N/A15.04%N/ANCNANuCanaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALLRAllarity TherapeuticsN/A2.752.75CMMBChemomab TherapeuticsN/A4.574.57MTEXMannatech0.441.250.74NCNANuCanaN/A1.121.12Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALLRAllarity Therapeutics11.53%CMMBChemomab Therapeutics46.05%MTEXMannatech12.98%NCNANuCana44.00%Insider OwnershipCompanyInsider OwnershipALLRAllarity Therapeutics0.08%CMMBChemomab Therapeutics11.91%MTEXMannatech41.50%NCNANuCana31.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALLRAllarity Therapeutics1017.02 million4.43 millionNot OptionableCMMBChemomab Therapeutics2014.36 million12.65 millionNot OptionableMTEXMannatech2501.90 million1.10 millionNot OptionableNCNANuCana305.68 million1.82 millionNot OptionableNCNA, MTEX, ALLR, and CMMB HeadlinesRecent News About These CompaniesNuCana plc: NuCana Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business UpdateMarch 22, 2025 | finanznachrichten.deNuCana Reports Q4 EPS GBP (1) vs. GBP (14)March 21, 2025 | markets.businessinsider.comNuCana Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business UpdateMarch 20, 2025 | globenewswire.comNuCana Calls for Shareholder Vote on Key ResolutionsMarch 18, 2025 | tipranks.comBank Stocks Lead European Equities Traded in the US as American Depositary Receipts Higher in Tuesday TradingFebruary 25, 2025 | msn.comAurion Biotech Appoints Donald Munoz as Chief Financial OfficerFebruary 10, 2025 | businesswire.comEuropean Equities Traded in the US as American Depositary Receipts Fall in Monday TradingFebruary 3, 2025 | msn.comEuropean Equities Traded in the US as American Depositary Receipts Edge Lower in Wednesday TradingJanuary 22, 2025 | msn.comNUC-7738 by NuCana for Metastatic Melanoma: Likelihood of ApprovalJanuary 6, 2025 | pharmaceutical-technology.comNUC-7738 by NuCana for T-Cell Lymphomas: Likelihood of ApprovalDecember 30, 2024 | pharmaceutical-technology.comNUC-7738 by NuCana for Solid Tumor: Likelihood of ApprovalDecember 30, 2024 | pharmaceutical-technology.comEuropean Equities Traded in the US as American Depositary Receipts Lower in Friday Trading, Down 1.5% for WeekDecember 13, 2024 | msn.comNuCana Reports Third Quarter 2024 Financial Results and Provides Business UpdateNovember 25, 2024 | globenewswire.comNuCana’s NUC-3373 Shows Promise in Cancer TreatmentNovember 13, 2024 | markets.businessinsider.comEuropean Equities Traded in the US as American Depositary Move Higher in Monday TradingNovember 12, 2024 | msn.comNuCana announces initial data from Phase 1b/2 modular study of NUC-3373November 12, 2024 | markets.businessinsider.comNuCana Announces Encouraging Initial Data from Phase 1b/2 Modular Study of NUC-3373 in Combination with Pembrolizumab or DocetaxelNovember 11, 2024 | globenewswire.comEuropean Equities Traded in the US as American Depositary Receipts Rise FridayOctober 18, 2024 | msn.comTruist Financial Sticks to Their Buy Rating for Nucana (NCNA)October 16, 2024 | markets.businessinsider.comBaillie Gifford's Strategic Acquisition of NuCana PLC SharesOctober 4, 2024 | gurufocus.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNCNA, MTEX, ALLR, and CMMB Company DescriptionsAllarity Therapeutics NASDAQ:ALLR$1.13 +0.06 (+5.61%) Closing price 04:00 PM EasternExtended Trading$1.14 +0.01 (+0.53%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. Allarity Therapeutics, Inc. has a collaboration with Detsamma Investments Pty. Ltd. to develop Deflexifol for the treatment of solid tumors. The company was incorporated in 2004 and is headquartered in Boston, Massachusetts.Chemomab Therapeutics NASDAQ:CMMB$1.31 +0.02 (+1.55%) Closing price 04:00 PM EasternExtended Trading$1.31 0.00 (0.00%) As of 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.Mannatech NASDAQ:MTEX$11.25 +0.50 (+4.65%) Closing price 03:54 PM EasternExtended Trading$12.50 +1.25 (+11.11%) As of 06:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mannatech, Incorporated operates as a health and wellness company in the Americas, Europe, the Middle East, Africa, and the Asia-Pacific. The company develops, markets, and sells nutritional supplements; topical and skin care, and anti-aging products; and weight-management and fitness products. It primarily sells its products directly, as well as through e-commerce and network marketing channels. Mannatech, Incorporated was incorporated in 1993 and is headquartered in Flower Mound, Texas.NuCana NASDAQ:NCNA$0.55 -0.10 (-15.37%) Closing price 03:59 PM EasternExtended Trading$0.55 0.00 (-0.02%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company, through its technology, is developing ProTides medicines to overcome the limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells. Its pipeline includes NUC-3373, a chemical entity derived from the nucleoside analog 5-fluorouracil that is in Phase 1b/2 study in patients with metastatic colorectal cancer, Phase 2 clinical trial for the second-line treatment of patients with advanced colorectal cancer, and Phase 1b/2 modular clinical trial for patients with advanced solid tumors and lung cancer. It is also developing NUC-7738, a ProTide transformation of 3'-deoxyadenosine, which is in the Phase 2 part of a Phase 1/2 clinical trial for patients with advanced solid tumors. The company has an assignment, license, and collaboration agreement with Cardiff ProTides Ltd to discover, drug design, and in vitro screen purine and pyrimidine-based nucleosides as potential drug candidates. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas If You Wanted To Buy AbbVie and Didn’t, There’s Still Time To Buy 3 Stocks To Watch For When Tariffs Subside 3 Boring Stocks Outperforming the Market This Year Short Sellers Gave Up on These 3 Names Recently Market Anticipation Builds: Joby Stock Climbs Ahead of Earnings Is Intuitive Surgical a Buy After Volatile Reaction to Earnings? Now Is the Time to Buy ServiceNow—The Rebound Is Real Archer Aviation Gets Analyst Target Upgrade: Time to Load Up? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
